All In MedTech

FDA Clearance Tracker · P810031-S065

Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 29, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 29, 2019

Approved

Time to decision

147 days

Received Dec 3, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P810031-S065
Device name
Sodium Hyaluronate Ophthalmic Viscoelastic Devices (OVD)
Applicant location
Irvine, CA
Received
Dec 3, 2018
Decided
Apr 29, 2019
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P810031

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

Approval for Healon GV® PRO, a modification of the Healon5 PRO OVD with the sodium hyaluronate concentration changed from 23 mg/mL to 18 mg/mL. The device, as modified, will be marketed under the trade name Sodium Hyaluronate Ophthalmic Viscoelastc Device (OVD), Healon GV® PRO and is indicated for use in anterior segment ophthalmic surgical procedures of the human eye. The Healon GV® PRO OVD is designed to create and maintain a deep anterior chamber which facilitates manipulation inside the eye with reduced trauma to the corneal endothelium and other ocular tissues. The Healon GV® PRO OVD can also be used to efficiently separate and control ocular issues. The Healon GV® PRO OVD is not designed to have any pharmacological effect.

Source documents

Other decisions for Johnson & Johnson Surgical Vision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.